共 50 条
- [21] Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer PatientsCLINICAL COLORECTAL CANCER, 2021, 20 (04) : 314 - 317Moretto, RobertoRossini, DanieleCapone, IolandaBoccaccino, AlessandraPerrone, FedericaTamborini, ElenaMasi, GianlucaAntoniotti, CarlottaMarmorino, FedericaConca, VeronicaBorelli, BeatriceMartignetti, AngeloPecora, IreneSimionato, FrancescaCupini, SamantaAmbrosini, MargheritaManca, PaoloPietrantonio, FilippoFalcone, AlfredoCremolini, Chiara
- [22] Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patientsThe Pharmacogenomics Journal, 2014, 14 : 322 - 327F LoupakisC AntoniottiC CremoliniW ZhangD YangT WakatsukiP BohanesM SchirripaL SalvatoreG MasiV RicciF GrazianoA RuzzoL BenhaimF MarmorinoY NingR El-KhoueiryA FalconeH-J Lenz
- [23] REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors-Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Cousin, SophieBellera, Carine A.Guegan, Jean PhilippeGomez-Roca, Carlos A.Metges, Jean-PhilippeAdenis, AntoinePernot, SimonCantarel, CoralieKind, MicheleToulmonde, MaudBourcier, KevinSoubeyran, IsabelleBessede, AlbanItaliano, Antoine
- [24] Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancerCANCER MEDICINE, 2018, 7 (11): : 5382 - 5393Fogelman, DavidCubillo, AntonioGarcia-Alfonso, PilarLimon Miron, Maria LuisaNemunaitis, JohnFlora, DanielBorg, ChristopheMineur, LaurentVieitez, Jose M.Cohn, AllenSaylors, GeneAssad, AlbertSwitzky, JulieZhou, LiBendell, Johanna
- [25] Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network studyANNALS OF ONCOLOGY, 2018, 29 : 105 - 105Bekaii-Saab, T.Ou, F.Anderson, D.Ahn, D.Boland, P.Ciombor, K.Jacobs, N.Desnoyers, R.Cleary, J.Meyers, J.Chiorean, E.Pedersen, K.Barzi, A.Sloan, J.McCune, J.Lacouture, M.Lenz, H.Grothey, A.
- [26] A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic BRAF-mutated colorectal cancer refractory to standard therapy.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS262 - TPS262Vakkalagadda, ChetanMukit, SabeehaKocherginsky, MashaKircher, Sheetal MehtaKalyan, AparnaMulcahy, Mary FrancesBenson, Al BowenChandel, NavdeepMahalingam, Devalingam
- [27] Randomized phase II study of cetuximab vs. irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study): Compared with ICECREAM studyANNALS OF ONCOLOGY, 2017, 28Keiichiro, IshibashiMasato, NakamuraAkihito, TsujiYasutaka, TakinishiYoshiaki, ShindoToru, AoyamaJunichi, SakamotoKoji, ObaHideyuki, Mishima
- [28] Phase II study of metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with refractory metastatic colorectal cancer (MCRC).JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Moiseyenko, V.Chubenko, V.Protsenko, S.Mikhalichenko, T.Moiseyenko, F.Brezhnev, N.Moiseyenko, A.Kornilov, A.Zueva, E.Gorchakova, M.
- [30] A phase II study of ziv-aflibercept (Z) plus FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)Satoh, TarohDenda, TadamichiHamaguchi, TetsuyaSugimoto, NaotoshiUra, TakashiYamazaki, KentaroFujii, HirofumiKajiwara, TakeshiNakajima, Takako EguchiTakahashi, ShinOtsu, SatoshiKomatsu, YoshitoSasaki, ToruSunaga, YoshinoriYoshino, Takayuki